Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inhaled recombinant alpha-1 antitrypsin
- Development stage
- Unknown
- Lead developer
- Kamada
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Inhalation
01
Overview
Inhaled recombinant alpha-1 antitrypsin (AAT) is an enzyme replacement therapy being developed by Kamada for the treatment of alpha-1 antitrypsin deficiency (AATD). Administered via the eFlow nebulizer, this therapy delivers the protein directly to the lungs, which is the primary site of disease activity in most AATD patients. By restoring the protease-antiprotease balance, it inhibits neutrophil elastase, thereby protecting delicate lung tissue from proteolytic degradation and slowing the progression of emphysema. This approach potentially requires lower drug doses compared to intravenous infusions and offers improved patient convenience.
- Other names
- Inhaled AATRecombinant alpha-1 antitrypsin
02
Targets
CTSG (Cathepsin G)Factor XIaELANE (Human Neutrophil Elastase)PRTN3 (Proteinase 3)
Beyond the preview
Go deeper on Inhaled recombinant alpha-1 antitrypsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhaled recombinant alpha-1 antitrypsin.